SavedAdd your journal

Journals / Eurasian Journal of Medicine / 2020 / Cilt: 52 - Sayı: 1

Comparision of Radiochemotherapy Applications that Committing with Two Different Chemotherapies Route in Locally Advanced Lung Cancer

Meryem AKTAN
Hilal KIZILTUNÇ ÖZMEN
Orhan SEZEN
Burak ERDEMCİ
Burcu SAĞLAM ALAN
Sinan EZİRMİK
Mustafa Vecdi ERTEKİN
Pages
73–76
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Pre- and post-treatment tumor and lymph node dimensionssignificantly differed in both groups (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: This study investigated pre- and post-treatment tumor and lymph node dimension response ratesand differences between side-effect profiles in patients with locally advanced inoperable nonsmall-cell lungcancer (NSCLC) receiving radiotherapy (RT) and concurrent chemotherapy (CT).Materials and Methods: A total of 30 inoperable patients who had not previously received RT and having amean age of 58.73±8.65 years with sufficient hematological reserves and normal hepatic and renal functionswere included in the study.
📊
Key Findings & Data:Those with pleural effusion, supraventricular lymph node metastasis, and N3lymph node involvement were excluded.
💡
Conclusion & Impact:Pre- and post-treatment tumor and lymph node dimensionssignificantly differed in both groups (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: This study investigated pre- and post-treatment tumor and lymph node dimension response ratesand differences between side-effect profiles in patients with locally advanced inoperable nonsmall-cell lungcancer (NSCLC) receiving radiotherapy (RT) and concurrent chemotherapy (CT).Materials and Methods: A total of 30 inoperable patients who had not previously received RT and having amean age of 58.73±8.65 years with sufficient hematological reserves and normal hepatic and renal functionswere included in the study. Those with pleural effusion, supraventricular lymph node metastasis, and N3lymph node involvement were excluded. Group I (n=15) received a 21-day 75 mg/m2 cisplatin (D1) and 15mg/m2 vinorelbine (D1, D8), whereas Group II (n=15) received 45 mg/m2 paclitaxel and AUC2 carboplatinweekly. RT was administered using a linear accelerator device with the 3D conformal RT technique at 6-18MV energy with a 1.8-2 Gy fraction for 6-7 weeks.Results: Patients were randomized into Group I receiving RT and concurrent cisplatin–vinorelbine and GroupII receiving weekly paclitaxel–carboplatin CT. Pre- and post-treatment tumor and lymph node dimensionssignificantly differed in both groups (p

🔖

Cite This Article

AKTAN, M., ÖZMEN, H. K., SEZEN, O., ERDEMCİ, B., ALAN, B. S., EZİRMİK, S., ERTEKİN, M. V. (2022). Comparision of Radiochemotherapy Applications that Committing with Two Different Chemotherapies Route in Locally Advanced Lung Cancer. Eurasian Journal of Medicine, Cilt: 52 - Sayı: 1, 73–76. https://ajindex.com/articles/508863

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Detterbeck FC. Diagnosis and treatment of lung cancer, in An Evidence-Based Guide for the Practicing Physician. Phyledelphia, PA, WB Sounders, 2000
  2. Bulzebruck H, Bopp R, Drings P, et al. New aspects in the staging of lung cancer: Prospective validation of the International Union Against Cancer TNM classification. Cancer 1992; 70: 1102-10
  3. Govindan R. Management of patients with non-small cell lung cancer and poor performance status. Curr Treat Options Oncol 2003; 4: 55-9. [CrossRef] 4. Johnson DH, Turissi AT. Combined modality treatment for locally advanced, unresectable non-small cell lung cancer. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT, Minna JD, editors. Lung Cancer: Principles and Practice. 2nd ed. Philadelphia: Lippincott Williams and Wilkins 2000: 910- 20
  4. Rosen RJ. Smoking and Lung Cancer Mortality in the United States From 2015 to 2065. Ann Intern Med 2019; 170: 740. [CrossRef] 6. Parkin DM, Bray F, Ferlay J,Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74- 108. [CrossRef] 7. Ramaswamy AT, Toll BA, Chagpar AB, Judson BL. Smoking, cessation, and cessation counseling in patients with cancer: A population-based analysis. Cancer 2016; 122:1247-53. [CrossRef] 8. Ginsberg RS, Vokes EE, Raben A. Non-small cell lung cancer. In: DeVita VT Sr, Hellman S, Rosenberg SA; eds. Cancer: Principles and Practice of Oncology. 5th ed. Philadelphia, PA: Lippincott Raven; 1997; 858-911
  5. Hu W, Fang J, Nie J, et al. Efficacy and safety of extended use of platinum-based doublet che motherapy plus endostatin in patients with advanced nonsmall cell lung cancer. Medicine (Baltimore) 2016; 95: e4183. [CrossRef] 10. Artal Cortes A, Calera Urguizu L, Hernando Cubero J. Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art. Transl Lung Cancer Res 2015; 4: 191-7
  6. Grili R, Oxman AD, Julian JA. Chemotherapy for advanced Non-small Cell Lung Cancer: How much benefit is Enough? J Clin Oncol 1993; 11: 1866-72. [CrossRef] 12. Le Chevalier, R Arriagada, P Baldeyrou, et al. Inoperable Lung Epidermoid Cancer Non Metastasizing. A Phase II Trial Using Radiotherapy and Combined Chemotherapy. Bull Cancer 1985; 72: 25-9
  7. Klastersky J. VP-16 and cisplatin in the treatment of non small cell lung cancer. Semin Oncol 1985; 12: 17-20
  8. Depierre A, Chastang C, Quoix E, et al. Vinorelbine Versus Vinorelbine Plus Cisplatin in Advanced Non-Small Cell Lung Cancer: A Randomized Trial. Ann Oncol 1994; 5: 37-42. [CrossRef] 15. Gralla